維基百科

蘭尼單抗

維基百科中的醫學內容僅供參考，並不能視作專業意見。如需獲取醫療幫助或意見，請諮詢專業人士。詳見醫學聲明。

蘭尼單抗（英語：Ranibizumab，也譯為雷珠單抗，商品名Lucentis）是一種單克隆抗體片段（FAB），其與貝伐單抗（bevacizumab）是從相同親本鼠抗體獲得。它比母體分子小得多，能更緊密的結合到血管內皮生長因子-A(VEGF-A)。它是一種血管生成抑制劑(angiogenesis inhibitor)，已被批准用於治療的「濕」型老年黃斑變性。

蘭尼單抗
單克隆抗體
種類Fab片段（英語：Fab fragment）
目標血管內皮生長因子A（英語：Vascular endothelial growth factor A）（VEGF-A）
臨床資料
商品名（英語：Drug nomenclature）Lucentis, others
生物相似藥Ranibizumab-nuna,[1] Ranibizumab-eqrn,[2] Byooviz,[1][3] Cimerli,[2] Ranivisio,[4] Susvimo,[5] Ximluci[6]
AHFS/Drugs.comMonograph
MedlinePlusa607044
核准狀況
懷孕分級
給藥途徑靜脈注射
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物半衰期約9天[10]
識別資訊
CAS號347396-82-1  checkY
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
化學資訊
化學式C2158H3282N562O681S12
摩爾質量48,379.97 g·mol−1

參考資料

  1. ^ 1.0 1.1 1.2 Byooviz Nuna- ranibizumab injection, solution. DailyMed. 2022-04-27 [2022-08-02]. （原始內容存檔於2022-08-03）. 
  2. ^ 2.0 2.1 2.2 Cimerli- ranibizumab-eqrn injection, solution. DailyMed. 2022-10-19 [2023-01-21]. （原始內容存檔於2023-01-21）. 
  3. ^ 3.0 3.1 Byooviz EPAR. European Medicines Agency. 2021-06-23 [2021-09-09]. （原始內容存檔於2021-09-10）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ 4.0 4.1 Ranivisio EPAR. European Medicines Agency (EMA). 2022-06-20 [2022-10-06]. （原始內容存檔於2022-10-06）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ 5.0 5.1 Susvimo- ranibizumab injection, solution. DailyMed. [2021-12-19]. （原始內容存檔於2021-12-19）. 
  6. ^ 6.0 6.1 Ximluci EPAR. European Medicines Agency. 2022-09-14 [2023-03-03]. （原始內容存檔於2023-03-13）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ 7.0 7.1 AusPAR: Ranibizumab. Therapeutic Goods Administration (TGA). 2014-12-09 [2021-09-20]. （原始內容存檔於2021-09-21）. 
  8. ^ 8.0 8.1 https://www.tga.gov.au/resources/auspmd/byooviz [裸露網址]
  9. ^ Summary Basis of Decision - Byooviz. Health Canada. 2022-08-12 [2022-09-29]. （原始內容存檔於2022-09-29）. 
  10. ^ 10.0 10.1 Lucentis- ranibizumab injection, solution. DailyMed. [2021-09-20]. （原始內容存檔於2021-09-21）. 
  11. ^ Lucentis EPAR. European Medicines Agency. 2018-09-17 [2021-09-09]. （原始內容存檔於2021-09-10）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

外部連結

取自「https://zh.wikipedia.org/w/index.php?title=兰尼单抗&oldid=80155780」